OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced three abstracts to be presented at the 36 th EORTC-NCI-AACR (ENA) Symposium 2024 from October 23-25, in Barcelona, Spain ...

IMMULAB: A phase II trial of immunotherapy with pembrolizumab in combination with local ablation for patients with early stage hepatocellular carcinoma (HCC)—The IKF-IMMULAB trial. Trastuzumab ...

Huons Global Co. Ltd. has described reversible H+/K+ ATPase inhibitors, particularly acid pump antagonists (APA), reported to be useful for the treatment of gastric and duodenal ulcers, gastritis, ...

Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1, may lower the rate of pulmonary exacerbations in patients with bronchiectasis. New research findings are summarized in a short ...

Testicular germ cell tumor survival among children, adolescents, and young adults: A population-based retrospective cohort study. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I.

BTK inhibitors have transformed B-cell malignancy treatment, with distinct resistance mechanisms linked to specific inhibitors. Covalent inhibitors often lead to BTK C481 mutations, while non-covalent ...